Mubadala Investment Company has agreed to acquire a minority stake in U.S.-based healthcare technology firm Zelis. This deal marks a significant move in Mubadala’s healthcare investments, reflecting its strategic focus on expanding into healthcare IT and payer-provider technologies. Mubadala leads the transaction alongside co-investors Norwest and HarbourVest, with Parthenon and Bain Capital retaining majority ownership of Zelis. The financial terms of the deal remain undisclosed.
Mubadala Investment Company, the Abu Dhabi sovereign wealth fund, is nearing a significant investment by acquiring a minority stake in the U.S.-based healthcare technology firm Zelis. The deal values Zelis, which specializes in cost management and payments for healthcare providers and insurers, at approximately $17 billion. This investment is part of Mubadala’s broader strategy to diversify its portfolio and expand its footprint in high-growth sectors such as healthcare technology.
In addition to its investment in Zelis, Mubadala is actively pursuing opportunities in China and India. These regions are attractive due to their growing demand for healthcare innovations and robust technology sectors. Mubadala’s strategy highlights its global approach to identifying and nurturing emerging markets and industries.
This move aligns with Mubadala’s track record of investing in transformative industries worldwide, reinforcing its position as a key player in global innovation and economic development
Zelis operates a platform that digitizes healthcare payments, collaborating with 770 U.S. insurers to streamline claim management and provider negotiations. According to Mina Hamoodi, head of healthcare investments at Mubadala, this is the company’s largest healthcare investment to date and an entry into critical subsectors like payer-provider technology.
Beyond the U.S., Mubadala is eyeing investments in Asia, particularly in China and India. Despite geopolitical and economic uncertainties, the company views China as ripe for investment, emphasizing businesses with localized supply chains and strong cash flows. Recent figures show Middle Eastern firms have already invested a record $9 billion in Greater China this year.
India remains another core focus due to its rapidly expanding middle class and increasing demand for healthcare and education. Mubadala recently invested in Manipal Health Enterprises, which operates over 30 hospitals across India, treating six million patients annually.
These efforts align with Mubadala’s broader strategy to diversify its portfolio and support transformative industries globally, extending its reach across sectors like life sciences, pharmaceuticals, and healthcare technology.
